TY - JOUR
T1 - Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant
AU - Gaballa, Sameh
AU - Saliba, Rima M.
AU - Srour, Samer
AU - Lu, Gary
AU - Brammer, Jonathan E.
AU - Shah, Nina
AU - Bashir, Qaiser
AU - Patel, Krina
AU - Bock, Fabian
AU - Parmar, Simrit
AU - Hosing, Chitra
AU - Popat, Uday
AU - Delgado, Ruby
AU - Rondon, Gabriela
AU - Shah, Jatin J.
AU - Manasanch, Elisabet E.
AU - Orlowski, Robert Z.
AU - Champlin, Richard
AU - Qazilbash, Muzaffar H.
N1 - Publisher Copyright:
© 2016 Wiley Periodicals, Inc.
PY - 2016/10/1
Y1 - 2016/10/1
N2 - TP53 gene deletion is associated with poor outcomes in multiple myeloma (MM). We report the outcomes of patients with MM with and without TP53 deletion who underwent immunomodulatory drug (IMiD) and/or proteasome inhibitor (PI) induction followed by autologous hematopoietic stem cell transplant (auto-HCT). We identified 34 patients with MM and TP53 deletion who underwent IMiD and/or PI induction followed by auto-HCT at our institution during 2008–2014. We compared their outcomes with those of control patients (n = 111) with MM without TP53 deletion. Median age at auto-HCT was 59 years in the TP53-deletion group and 58 years in the control group (P = 0.4). Twenty-one patients (62%) with TP53 deletion and 69 controls (62%) achieved at least partial remission before auto-HCT (P = 0.97). Twenty-three patients (68%) with TP53 deletion and 47 controls (42%) had relapsed disease at auto-HCT (P = 0.01). Median progression-free survival was 8 months for patients with TP53 deletion and 28 months for controls (P < 0.001). Median overall survival was 21 months for patients with TP53 deletion and 56 months for controls (P < 0.001). On multivariate analysis of both groups, TP53 deletion (hazard ratio 3.4, 95% confidence interval 1.9–5.8, P < 0.001) and relapsed disease at auto-HCT (hazard ratio 2.0, 95% confidence interval 1.2–3.4, P = 0.008) were associated with a higher risk of earlier progression. In MM patients treated with PI and/or IMiD drugs, and auto-HCT, TP53 deletion and relapsed disease at the time of auto-HCT are independent predictors of progression. Novel approaches should be evaluated in this high-risk population. Am. J. Hematol. 91:E442–E447, 2016.
AB - TP53 gene deletion is associated with poor outcomes in multiple myeloma (MM). We report the outcomes of patients with MM with and without TP53 deletion who underwent immunomodulatory drug (IMiD) and/or proteasome inhibitor (PI) induction followed by autologous hematopoietic stem cell transplant (auto-HCT). We identified 34 patients with MM and TP53 deletion who underwent IMiD and/or PI induction followed by auto-HCT at our institution during 2008–2014. We compared their outcomes with those of control patients (n = 111) with MM without TP53 deletion. Median age at auto-HCT was 59 years in the TP53-deletion group and 58 years in the control group (P = 0.4). Twenty-one patients (62%) with TP53 deletion and 69 controls (62%) achieved at least partial remission before auto-HCT (P = 0.97). Twenty-three patients (68%) with TP53 deletion and 47 controls (42%) had relapsed disease at auto-HCT (P = 0.01). Median progression-free survival was 8 months for patients with TP53 deletion and 28 months for controls (P < 0.001). Median overall survival was 21 months for patients with TP53 deletion and 56 months for controls (P < 0.001). On multivariate analysis of both groups, TP53 deletion (hazard ratio 3.4, 95% confidence interval 1.9–5.8, P < 0.001) and relapsed disease at auto-HCT (hazard ratio 2.0, 95% confidence interval 1.2–3.4, P = 0.008) were associated with a higher risk of earlier progression. In MM patients treated with PI and/or IMiD drugs, and auto-HCT, TP53 deletion and relapsed disease at the time of auto-HCT are independent predictors of progression. Novel approaches should be evaluated in this high-risk population. Am. J. Hematol. 91:E442–E447, 2016.
UR - http://www.scopus.com/inward/record.url?scp=84990223940&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84990223940&partnerID=8YFLogxK
U2 - 10.1002/ajh.24487
DO - 10.1002/ajh.24487
M3 - Article
C2 - 27420405
AN - SCOPUS:84990223940
SN - 0361-8609
VL - 91
SP - E442-E447
JO - American journal of hematology
JF - American journal of hematology
IS - 10
ER -